Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363200 | 0.89 | IL2 (0.48) | IDO1IL2 | |
| SCHEMBL16363199 | 0.89 | IDO1 (0.42) | IDO1S1PR1 | |
| SCHEMBL1827067 | 0.85 | IDO1 (0.49) | IDO1P2RX1P2RX7CRACR2AMEN1 | |
| SCHEMBL1827437 | 0.84 | RAB9A (0.46) | IDO1CRACR2ATDP1 | |
| SCHEMBL16363194 | 0.82 | IDO1 (0.52) | IDO1P2RX1P2RX7CRACR2AS1PR1 | |
| SCHEMBL1827873 | 0.79 | IDO1 (0.45) | IDO1P2RX1P2RX7CRACR2AIL2 | |
| SCHEMBL27635478 | 0.79 | MEN1 (0.52) | IDO1MEN1KMT2ATDP1 | |
| SCHEMBL1825803 | 0.79 | IDO1 (0.47) | IDO1P2RX1P2RX7CRACR2AIL2 | |
| SCHEMBL1828878 | 0.78 | RAB9A (0.43) | IDO1CRACR2ATDP1 | |
| SCHEMBL1824963 | 0.77 | ALDH1A1 (0.43) | IDO1CRACR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | IDO1 249/4885P2RX1 460/4885P2RX7 211/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | IDO1 249/4885P2RX1 460/4885P2RX7 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.